KR102637541B1 - 화합물, 조성물 및 방법 - Google Patents

화합물, 조성물 및 방법 Download PDF

Info

Publication number
KR102637541B1
KR102637541B1 KR1020197036801A KR20197036801A KR102637541B1 KR 102637541 B1 KR102637541 B1 KR 102637541B1 KR 1020197036801 A KR1020197036801 A KR 1020197036801A KR 20197036801 A KR20197036801 A KR 20197036801A KR 102637541 B1 KR102637541 B1 KR 102637541B1
Authority
KR
South Korea
Prior art keywords
optionally substituted
disease
alkyl
compounds
hexahydropyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197036801A
Other languages
English (en)
Korean (ko)
Other versions
KR20200006120A (ko
Inventor
조르지오 보나노미
앤서니 에이. 에스트라다
지안웬 에이. 펭
브라이언 폭스
신지아 마리아 프란시니
쳉 후
콜린 필립 레슬리
막심 오시포브
아난타 수다카르
자카리 케이. 스위니
자비에 드 비센테 피달고
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Publication of KR20200006120A publication Critical patent/KR20200006120A/ko
Application granted granted Critical
Publication of KR102637541B1 publication Critical patent/KR102637541B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020197036801A 2017-05-17 2018-05-17 화합물, 조성물 및 방법 Active KR102637541B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507682P 2017-05-17 2017-05-17
US62/507,682 2017-05-17
PCT/US2018/033269 WO2018213634A1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods

Publications (2)

Publication Number Publication Date
KR20200006120A KR20200006120A (ko) 2020-01-17
KR102637541B1 true KR102637541B1 (ko) 2024-02-15

Family

ID=64274734

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036801A Active KR102637541B1 (ko) 2017-05-17 2018-05-17 화합물, 조성물 및 방법

Country Status (11)

Country Link
US (2) US11174262B2 (enExample)
EP (1) EP3625234B1 (enExample)
JP (2) JP7140781B2 (enExample)
KR (1) KR102637541B1 (enExample)
CN (1) CN110914275A (enExample)
AU (2) AU2018269745C1 (enExample)
BR (1) BR112019023979A2 (enExample)
CA (1) CA3063938A1 (enExample)
IL (1) IL270505B2 (enExample)
MX (1) MX2019013642A (enExample)
WO (1) WO2018213634A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552017B1 (en) * 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
WO2018213634A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods
WO2022046905A1 (en) * 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
WO2023076133A1 (en) * 2021-10-27 2023-05-04 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof
WO2025045281A2 (zh) * 2023-08-31 2025-03-06 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
JP2008505976A (ja) 2004-07-12 2008-02-28 アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド テトラペプチド類似体
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP2009544728A (ja) 2006-07-24 2009-12-17 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
JP2016500691A (ja) 2012-10-22 2016-01-14 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP6683712B2 (ja) * 2014-12-24 2020-04-22 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン ネクローシス阻害薬
WO2018213634A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
JP2008505976A (ja) 2004-07-12 2008-02-28 アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド テトラペプチド類似体
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP2009544728A (ja) 2006-07-24 2009-12-17 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
JP2016500691A (ja) 2012-10-22 2016-01-14 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods

Also Published As

Publication number Publication date
WO2018213634A1 (en) 2018-11-22
CA3063938A1 (en) 2018-11-22
AU2018269745C1 (en) 2022-06-09
MX2019013642A (es) 2020-07-20
US11174262B2 (en) 2021-11-16
IL270505B2 (en) 2023-09-01
JP2020520925A (ja) 2020-07-16
IL270505A (enExample) 2019-12-31
CN110914275A (zh) 2020-03-24
IL270505B1 (en) 2023-05-01
AU2022202524A1 (en) 2022-05-12
EP3625234A4 (en) 2021-03-10
KR20200006120A (ko) 2020-01-17
US20200079784A1 (en) 2020-03-12
JP2022174180A (ja) 2022-11-22
AU2022202524B2 (en) 2023-10-05
AU2018269745A1 (en) 2019-11-28
JP7140781B2 (ja) 2022-09-21
EP3625234B1 (en) 2023-09-20
EP3625234A1 (en) 2020-03-25
AU2018269745B2 (en) 2022-01-27
US20220024938A1 (en) 2022-01-27
US11851433B2 (en) 2023-12-26
BR112019023979A2 (pt) 2020-06-09

Similar Documents

Publication Publication Date Title
US10709692B2 (en) Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
KR102637541B1 (ko) 화합물, 조성물 및 방법
TWI786049B (zh) 化合物、組合物及方法
TWI794232B (zh) 激酶抑制劑及其用途
JP7208137B2 (ja) 化合物、組成物および方法
JP2020530446A (ja) 化合物、組成物、及び、方法
BR112020011979A2 (pt) compostos de indol substituídos por amida úteis como inibidores de tlr
CA3072057A1 (en) Small molecule modulators of eukaryotic initiation factor 2b
AU2012324803A1 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP2012533602A (ja) 縮合アミノジヒドロピリミドン誘導体
CN111971287A (zh) 作为trk激酶抑制剂的大环化合物
WO2025076088A1 (en) Lactams for use as sarm1 inhibitors
HK40016450B (en) Compounds useful as ripk1 inhibitors
HK40034417A (en) Macrocyclic compounds as trk kinases inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210514

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230501

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231116

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240213

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240213

End annual number: 3

Start annual number: 1

PG1601 Publication of registration